Prosecution Insights
Prosecution Insights
2 pending office actions • 0 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Marizyme Inc. currently has 2 pending office actions. These matters are assigned to 2 distinct examiners, meaning each action is being reviewed by a different individual. The data reports 0 distinct art units for these filings, which is a notable characteristic of the company's current prosecution status.
The busiest examiner is TIWARI, VYOMA SHUBHAM, who manages 1 busiest examiner pending office action. Since there are 2 pending office actions in total, the workload is shared between the 2 distinct examiners. This creates a balanced prosecution workload across the portfolio, even with 0 distinct art units currently identified in the records.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TIWARI, VYOMA SHUBHAM | 1 | 31.5% | +48.1% |
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18855944 | POWDER FORMULATIONS AND USE THEREOF IN MEDICAL AND/OR SURGICAL PROCEDURES | MARVICH, MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18866089 | USE OF CYTOPROTECTANT FORMULATIONS IN CELL OR TISSUE TRANSPORT AND/OR STORAGE | TIWARI, VYOMA SHUBHAM | — |
| 18855944 | POWDER FORMULATIONS AND USE THEREOF IN MEDICAL AND/OR SURGICAL PROCEDURES | MARVICH, MARIA | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866089 | USE OF CYTOPROTECTANT FORMULATIONS IN CELL OR TISSUE TRANSPORT AND/OR STORAGE | TIWARI, VYOMA SHUBHAM | — | Other | Non-Final OA | — | Pending | Nov 15, 2024 |
| 18855944 | POWDER FORMULATIONS AND USE THEREOF IN MEDICAL AND/OR SURGICAL PROCEDURES | MARVICH, MARIA | — | §102§103§112 | Non-Final OA | — | Pending | Oct 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial